🟠 Moderate Evidence
Health workers, patients, and policymakers in Ethiopia harbour significant concerns about the safety and efficacy of two promising new treatments for Plasmodium vivax malaria, despite their potential to improve treatment adherence, according to a qualitative study published in BMJ Global Health. The research, conducted across Gamo Zone in South Ethiopia between February and September 2023, reveals that prior messaging about completing full-course antimalarial regimens has created barriers to acceptance of shorter, more convenient dosing schedules.
Key takeaways
- Health workers and patients in Ethiopia view shorter-course malaria treatments as promising but worry they may be less effective than standard 14-day regimens
- Safety concerns about increased daily doses and risk of haemolysis in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency remain a major barrier to uptake
- Public health messaging emphasizing treatment completion may paradoxically undermine acceptance of evidence-based shorter regimens
Study at a Glance
| Source | BMJ Global Health |
| Study type | Qualitative study with semistructured interviews and focus groups |
| Sample size | 58 semistructured interviews and 6 focus group discussions |
| Population | Clinical trial staff, health workers, health extension workers, and malaria patients |
| Country | Ethiopia (Gamo Zone, South Ethiopia Regional State) |
Stakeholder Concerns About Novel Malaria Treatments in Ethiopia
Key barriers to acceptance of high-dose primaquine and tafenoquine regimens, reported by health workers and patients
Source: Qualitative stakeholder interviews, BMJ Global Health 2023 | Georgian Medical Journal News
Why Shorter Treatments Face Skepticism
Plasmodium vivax malaria remains a significant public health challenge, particularly in sub-Saharan Africa and South Asia. Standard treatment requires 14 days of primaquine to eliminate dormant parasites (hypnozoites) and prevent relapse, but poor adherence undermines effectiveness. The researchers at Arba Minch General Hospital and health facilities in Gamo Zone investigated how stakeholders perceive two alternatives: a 7-day high-dose primaquine regimen and single-dose tafenoquine.
Among 58 respondents interviewed and 6 focus groups convened, a consistent pattern emerged: while participants recognized shorter treatments could solve adherence problems, they expressed deep concerns about safety and efficacy. Prior public health messaging that emphasized completing the full 14-day course had created an implicit belief that shorter regimens might not work, the authors noted in their BMJ Global Health report.
This reflects a broader challenge in malaria elimination efforts across global health initiatives: public health messaging, while well-intentioned, can create unintended psychological barriers to accepting improved treatments.
Safety Concerns Dominate the Discussion
The most significant barrier identified was fear of haemolysis (destruction of red blood cells) in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency, a genetic condition common in malaria-endemic regions. Both high-dose primaquine and tafenoquine carry elevated haemolysis risk in G6PD-deficient individuals, and stakeholders worried that testing protocols might miss at-risk patients.
Health workers also raised concerns about overdosing—a fear amplified by the visible increase in daily pill dose under the new regimens compared to standard treatment. Pill number, shape, and colour influenced perceptions of safety, the qualitative analysis revealed. Some participants expressed worry that more pills per day signalled greater toxicity, regardless of the total drug exposure.
The study provides no quantitative safety comparison between the regimens but documents that stakeholder perceptions, whether scientifically grounded or not, will likely determine real-world uptake of these clinical innovations.
Both the 7-day high-dose primaquine regimen and single-dose tafenoquine were viewed as promising solutions to adherence challenges, but concerns about effectiveness and safety—rooted in prior public health messaging and fears of drug-induced haemolysis—remained significant barriers to acceptance.
— Qualitative study team, Arba Minch General Hospital and Gamo Zone health facilities (BMJ Global Health, 2023)
Implications for Policy and Implementation
The research underscores a critical gap between clinical evidence and stakeholder acceptance. Health policymakers designing communication strategies for malaria elimination programmes must acknowledge that previous messaging about 14-day treatment completion has created cognitive anchors that shorter regimens cannot easily dislodge. This suggests a need for targeted, transparent communication about the safety data supporting novel treatments.
The authors recommend that national malaria control programmes in Ethiopia and similar settings develop clear messaging addressing G6PD screening, haemolysis risk stratification, and the clinical evidence supporting shortened regimens. Without such messaging, even effective new treatments may languish due to low uptake among both patients and health workers.
This qualitative work complements clinical trial data and highlights why health policy implementation requires not just efficacy evidence but understanding of stakeholder risk perception. Similar studies in other malaria-endemic regions could strengthen the evidence base for implementation strategies globally.
What this means
Frequently asked questions
What is G6PD deficiency and why does it matter for malaria treatment?
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a genetic variation affecting red blood cell metabolism. Certain antimalarials, including primaquine and tafenoquine, can trigger haemolysis (red cell destruction) in G6PD-deficient individuals, causing anaemia and, rarely, severe complications. G6PD testing before treatment can identify at-risk patients and allow clinicians to adjust dosing or select alternative treatments.
How much faster is tafenoquine compared to primaquine?
Tafenoquine offers single-dose radical cure, while standard primaquine requires 14 days. The 7-day high-dose primaquine regimen is faster than standard but not as convenient as tafenoquine. This study did not directly compare efficacy, but both shorter regimens aim to improve patient completion and reduce relapse risk.
Why would shorter treatment be harder to accept if it is more convenient?
The qualitative research shows that prior public health messaging emphasizing completion of full 14-day courses created a psychological belief that shorter regimens might be inadequate or risky. Additionally, visible increases in daily pill dose (even if total drug exposure is similar or lower) triggered overdose concerns. Overcoming these perceptions requires transparent communication backed by clinical evidence.
As malaria elimination campaigns intensify across sub-Saharan Africa and Asia-Pacific regions, the gap between clinical innovation and stakeholder acceptance will only widen without deliberate communication strategy. This Ethiopian qualitative study serves as a model for other malaria programmes seeking to implement novel treatments—showing that evidence of efficacy alone is insufficient. Policymakers must invest in understanding and addressing the specific risk perceptions that shape whether health workers prescribe and patients accept these life-saving regimens.
Source: Risk perceptions of high-dose primaquine and tafenoquine among Plasmodium vivax malaria stakeholders in Ethiopia: a qualitative study, BMJ Global Health
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
